

STUDY CONFIRMS NEW NASAL SWAB IS MOST ACCURATE, COMFORTABLE AND EASY FOR KIDS

- A new study by the Murdoch Children’s Research Institute has confirmed that the Rhinoswab Junior™ nasal swab:
 - can be readily used by children to self-collect,
 - is more comfortable and preferred to the standard combined nose and throat swabs,
 - is highly sensitive and accurate for SARS-CoV-2 detection, and
 - is more sensitive and has better COVID-19 case detection than saliva sampling.
- Study confirms Rhinoswabs™ would be the preferred method of sample collection for respiratory diseases for children whether for PCR or RAT testing.
- Rhinoswab benefits enable regular and repeat testing of children for a range of respiratory viruses at home, in schools and health settings.

26th September 2022: Rhinomed Limited (ASX:RNO OTCQB:RHNMF), a leader in wearable nasal and respiratory technology including nasal diagnostics, is pleased to advise of the forthcoming publication of a further study and data by researchers from the [Murdoch Children’s Research Institute and the Royal Children’s Hospital \(RCH\) Melbourne](#) confirming the efficacy and comfort of the world’s first nasal swab designed specifically for children – the Rhinoswab Junior.

The “**Less invasive SARS-CoV-2 testing for children: A comparison of saliva and a novel Anterior Nasal Swab**”¹ compared the current standard of care combined nose and throat swabs to saliva collection and to Rhinomed’s novel anterior nasal swab. Study samples were self-collected by 53 children aged 4-18 years.

The study demonstrates Rhinoswab Junior is the superior method for collecting samples from children when considering comfort, consistency, accuracy and efficacy.

Rhinoswab Junior’s unique design and ease of use means even children can self-administer sampling, and parents and carers are more likely to ensure children are tested. Rhinoswabs have potential to significantly improve testing rates and accuracy and, as a result, case detection across populations, especially children and other vulnerable groups.

In this study Rhinoswab was preferred by 88% of children when compared with the combined nose and throat swab. This builds on a [previous Murdoch Children’s Research Institute study of 249 hospital samples](#) that concluded that the Rhinoswab Junior is clinically equivalent to a standard combined nose and throat swab, yet preferred by eight out of 10 children as well by parents and nursing staff².

The 19th Royal Children’s Hospital National Child Health Poll³ identified that 74% of parents were reluctant to bring their children in for COVID-19 testing because of potential trauma and pain, with up to 30% unlikely to test their children due to current sampling methods. The new Murdoch Children’s Research Institute & Royal

¹ <https://www.medrxiv.org/content/10.1101/2022.09.21.22280208v1>

² https://cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research/1.0/file/2924-02469551-3A584290?access_token=83ff96335c2d45a094df02a206a39ff4

³ <https://www.rchpoll.org.au/polls/covid-19-testing-in-kids-what-concerns-parents/>

RHINOMED

MAKE EVERY BREATH COUNT

Children’s Hospital study confirms Rhinoswab Junior provides a comfortable alternative that addresses these concerns.

These results come at a time when case detection continues to be a critical part of the public health response to the ongoing SARS-CoV-2 pandemic including new variants. The results from this study confirm that Rhinoswab Junior provides a feasible and acceptable method for SARS-CoV-2 case testing and detection in children.

In this study Rhinoswab samples proved highly sensitive to SARS-CoV-2 detection by polymerase chain reaction (PCR) compared with saliva samples. All 44 SARS-CoV-2 combined throat and nasal (CTN) swab detections were also detected by the Rhinoswab sample (sensitivity 1.000 (95%CI 0.920, 1.000) with an additional positive SARS-CoV-2 detection in a Rhinoswab sample not detected in the CTN sample. By comparison, saliva samples detected 39 of the 44 CTN detections (sensitivity 0.886, 95%, CI 0.754, 0.962).

In July 2022 SureScreen Australia successfully registered the first rapid antigen test kit using the Rhinoswab Junior with the Australian Register of Therapeutic Goods enabling sales into the Australian, New Zealand, Singapore and South Pacific markets. These kits are now available for sale in Australia via [SureScreen Australia](#).

Rhinomed CEO Michael Johnson commented, “With SARS-CoV-2 variants continuing to evolve, we need more accurate, consistent and comfortable sample collection methods to encourage people – especially children and vulnerable populations – to keep getting tested. The new Murdoch Children’s Research Institute study confirms that Rhinoswab Junior is the preferred sampling method. Rhinomed is proud to have developed a swab that not only works better, but removes anxiety and distress – not just for the children but for their parents and health care workers. [Even adults prefer Rhinoswabs](#).⁴ We are grateful to have the Murdoch Children’s Research Institute and The Royal Children’s Hospital’s rigorous research demonstrate the benefits of Rhinoswab Junior.”

Rhinoswab works with existing pathology workflows and equipment, and has an equivalent cost and quality of standard US and European swabs. The study paper has been submitted to journals for publication.

Further information about the Rhinoswab can be found at <https://www.rhinomed.global/about-rhinomed/sample-collection/>.

This report has been authorised for release to the market by the Board.

Company	Investor and Media Relations
Michael Johnson, CEO & Director +61 (0) 3 8416 0900 mjohnson@rhinomed.global Follow us on Twitter @rhinomedceo	Rudi Michelson Monsoon Communications +61(0) 411 402 737 rudim@monsoon.com.au

About Rhinomed Limited (ASX: RNO, OTCQB:RHNMF)

Rhinomed Limited is a nasal and airway technology company developing and selling innovative products that improve breathing, help the diagnosis of upper respiratory diseases and potentially enable more effective drug delivery. Rhinomed has a range of FDA, TGA and CE Mark registered nasal devices on the market that improve breathing (including for athletes), sleep and snoring, with increasing global sales in thousands of retail and online outlets. This includes Mute, the leading internal anti-snoring nasal dilator in the USA, which grew its sales 40% on Amazon by 156% in 2022. Rhinoswab is a more comfortable, reliable nasal swab for sample self-collection for testing COVID-19 and other respiratory viruses. This is Rhinomed’s entry into the diagnostics market. In multiple user trials Rhinoswab was the preferred swab by over 75% of users and highly rated on comfort. Its companion product, the child friendly Rhinoswab Junior, has also proven to be effective and strongly preferred by children, parents and nurses in trials by the Murdoch Children’s Research Institute and Royal Children’s Hospital, Melbourne. The Rhinoswab range is registered with the FDA, MHRA, TGA and awarded a CE Mark with registrations pending in other markets.

⁴ <https://www.pathology.health.nsw.gov.au/research/research-forum/research-forum-2021/christopher-kot>